FITC-Linked Polyclonal Antibody to Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14)
| Code | Size | Price |
|---|
| LAA827Mu81-200ul | 200ul | £273.00 |
Quantity:
| LAA827Mu81-1ml | 1ml | £637.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Documents
Further Information
Alternative Names:
CD258; TR2; HVEML; LIGHT; LTg; Herpes virus entry mediator ligand; Herpesvirus entry mediator ligand
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Tumor Necrosis Factor Ligand Superfamily, Member 14
Reactivity:
Ra;
Source:
Antibody labeling
Usage:
Western blotting: 0.5-2ug/mL
Immunocytochemistry in formalin fixed cells: 5-20ug/mL
Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL
Immunohistochemistry in paraffin section: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunocytochemistry in formalin fixed cells: 5-20ug/mL
Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL
Immunohistochemistry in paraffin section: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Polyclonal Antibody to Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14) | PAA827Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||